Injection site reactions on GLP-1 medications

What the labels count as a reaction

An injection site reaction is any local effect where the medicine went in. The labels group several terms under it. The Zepbound® label includes bruising, redness (erythema), itching (pruritus), pain, rash and general reactions at the site ^[3]. The Wegovy® label lists itching, redness, inflammation, hardening (induration) and irritation; the Ozempic® label gives discomfort and redness as examples ^[5][6]. The Canadian Zepbound® monograph uses a longer list that also takes in swelling, bleeding and a blood collection under the skin (haematoma) ^[11].

Section 6.1 of each label also reminds readers that rates from different trials cannot be directly compared, so the table below shows each label’s own figures side by side rather than ranking the medicines.

Trial rates against placebo

Rows come from each US label’s placebo-controlled trials. The Ozempic® label gives no placebo figure for this reaction.

European and Canadian product information

The European Medicines Agency sorts side effects by frequency class. It lists injection site reactions as “common” (at least 1 person in 100) for Mounjaro® and Wegovy®, and “uncommon” (at least 1 in 1,000) for Ozempic®, where 0.6% on 0.5 mg and 0.5% on 1 mg reported them, usually mildly ^[8][9][10]. There is no European Zepbound® document: in the EU, tirzepatide is sold only as Mounjaro®.

The European Mounjaro® information gives rates for four trial pools: 3.2% versus 0.4% in type 2 diabetes, 8.0% versus 1.8% in weight management, 8.2% versus 2.6% in sleep apnoea and 6.0% versus 1.6% in heart failure. It also lists injection site pain separately, as uncommon ^[8]. The Canadian Zepbound® monograph reports 8.0% versus 1.8% across SURMOUNT-1 to -3 ^[11].

The antibody finding in the tirzepatide labels

The Mounjaro® and Zepbound® labels add a detail the semaglutide labels do not. In their trials, many people developed antibodies to tirzepatide: 51% in the seven Mounjaro® trials and 64.5% in Zepbound® Studies 1 and 2. Injection site reactions were more frequent in those people: 4.6% versus 0.7% without antibodies in the Mounjaro® pool, and 11.3% versus 1% in the Zepbound® pool ^[1][3]. The Canadian monograph, pooling four SURMOUNT trials, reports 13.6% versus 1.8% ^[11].

This is an association, not proof that the antibodies cause the reactions. The European Mounjaro® information says there was no sign that antibodies changed how the medicine was handled in the body or how well it worked ^[8]. These antibodies were measured by laboratory tests within the trials; the labels do not suggest testing for them in routine care, and say antibody rates from different tests cannot be meaningfully compared.

Where the labels say to inject

• Under the skin (subcutaneously) of the stomach area, thigh or upper arm; never into a muscle or vein. The Mounjaro® and Zepbound® guides say the back of the upper arm should be injected by another person ^[2][4].
• Rotate the injection site with each injection. The Zepbound® guide adds that you may use the same body area but should choose a different site within it ^[4].
• If you also use insulin, the Ozempic® and Mounjaro® guides say not to mix them in one injection; they may go in the same body area, but not right next to each other ^[2][5].
• For Saxenda®, the label says to rotate sites within the same region to reduce the risk of cutaneous amyloidosis, a skin change listed among its postmarketing reports ^[7].
• Never share a pen, even with a new needle, because of the risk of passing on infections.

Why rotation matters

Rotation is less about this week’s red patch and more about the skin over months. The Canadian Mounjaro® instructions say changing the site lowers the risk of lipodystrophy, which shows as pits or thickened skin, and of localised cutaneous amyloidosis, lumps formed by a protein build-up under the skin ^[12]. The US Saxenda® label names the same skin change, cutaneous amyloidosis, for liraglutide ^[7].

The Canadian instructions also list where not to inject: skin that is tender, bruised, scaly or hard, scars or damaged skin, skin with pits, thickening or lumps, and the same spot used for another medicine ^[11][12].

Why it may happen

What the labels support: in the tirzepatide trials, reactions were linked with antibodies to the medicine, and in the Mounjaro® and Zepbound® weight trials they were more common than on placebo ^[1][3][8]. Placebo injections were also followed by reactions in up to about 1 in 40 people in these pools, which suggests part of what people notice may come from the injection itself rather than the medicine.

What is proposed but not measured: why some people develop antibodies and others do not is not explained in the labels, and neither is whether technique changes the rate.

General medical background: MedlinePlus explains that a break in the skin can let normal skin bacteria cause an infection called cellulitis, which is different from a local reaction to the medicine ^[13].

What else could it be

A skin infection: MedlinePlus lists redness or swelling that keeps growing, warmth, pain or tenderness, a tight shiny look to the skin, and fever with chills as signs of cellulitis ^[13].

An allergic reaction rather than a local one: in the Mounjaro® placebo-controlled pool, hypersensitivity reactions were reported in 3.2% of people on the medicine and 1.7% on placebo. In the Zepbound® trials most of these were skin reactions such as rash or itching, and immediate reactions within a day of the dose occurred in 2.1% versus 0.4% on placebo ^[1][3].

A simple bruise from the needle: the Zepbound® label counts bruising under its injection site heading, and the instructions say to press lightly, without rubbing, if you see blood ^[3][11].

What the instructions say helps

The labels do not recommend creams, ice or medicines for a site reaction, and the manufacturers do not either. What the instructions do give is practical technique, which is worth following every time.

• If you see blood after removing the needle, press the site lightly with gauze or a cotton ball ^[6][11].
• Do not rub the injection site ^[11].
• Pick a new spot each time and avoid skin that is already tender, bruised, hard, scarred or lumpy ^[11][12].
• If a reaction bothers you, ask your pharmacist or prescriber before putting anything on it, and mention it at your next visit.

What to write down

A useful note records the exact site, including left or right, the date and time of the injection, and how many hours or days later the reaction appeared. Describe what you saw: redness, itching, a bruise, a firm lump, pain, and roughly how large it was. Then note how long it took to fade and whether that spot had been used recently.

Over several weeks, a site log shows whether reactions keep appearing in one area, follow a reused spot or have stopped. That is concrete information to bring to your prescriber or pharmacist if reactions bother you.

Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Ozempic®, Wegovy® and Saxenda® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Eli Lilly and Company or Novo Nordisk.